-$0.51 EPS Expected for Prelude Therapeutics Incorporated (NASDAQ:PRLD) This Quarter

Equities analysts expect Prelude Therapeutics Incorporated (NASDAQ:PRLD) to post ($0.51) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Prelude Therapeutics’ earnings. The highest EPS estimate is ($0.49) and the lowest is ($0.53). The firm is expected to announce its next quarterly earnings report on Tuesday, August 10th.

According to Zacks, analysts expect that Prelude Therapeutics will report full year earnings of ($2.12) per share for the current year, with EPS estimates ranging from ($2.27) to ($1.97). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.43) per share, with EPS estimates ranging from ($4.75) to ($1.99). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Prelude Therapeutics.

Prelude Therapeutics (NASDAQ:PRLD) last issued its earnings results on Tuesday, March 16th. The company reported ($0.45) earnings per share for the quarter.

PRLD has been the topic of a number of recent analyst reports. HC Wainwright started coverage on shares of Prelude Therapeutics in a report on Monday, April 26th. They set a “buy” rating and a $62.00 target price on the stock. Zacks Investment Research cut shares of Prelude Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 19th. Barclays started coverage on shares of Prelude Therapeutics in a research report on Tuesday, March 9th. They set an “overweight” rating and a $80.00 price objective for the company. Finally, Morgan Stanley lifted their price objective on shares of Prelude Therapeutics from $47.00 to $60.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 17th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $54.17.

Shares of PRLD opened at $32.04 on Tuesday. The firm has a market capitalization of $1.50 billion and a P/E ratio of -7.03. Prelude Therapeutics has a 1-year low of $23.69 and a 1-year high of $95.38. The stock’s fifty day moving average price is $36.63.

In related news, insider Peggy Scherle sold 15,370 shares of the company’s stock in a transaction dated Wednesday, April 7th. The shares were sold at an average price of $39.31, for a total transaction of $604,194.70. Following the completion of the sale, the insider now owns 15,383 shares of the company’s stock, valued at $604,705.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David J. Mauro sold 25,000 shares of the company’s stock in a transaction dated Monday, April 19th. The stock was sold at an average price of $30.89, for a total transaction of $772,250.00. Following the sale, the insider now directly owns 25,000 shares of the company’s stock, valued at approximately $772,250. The disclosure for this sale can be found here. In the last three months, insiders sold 92,826 shares of company stock valued at $3,324,858. 77.38% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of PRLD. Pacer Advisors Inc. bought a new stake in Prelude Therapeutics during the first quarter worth about $49,000. IFP Advisors Inc acquired a new position in Prelude Therapeutics during the first quarter worth about $52,000. E Fund Management Co. Ltd. acquired a new position in Prelude Therapeutics during the first quarter worth about $87,000. Citigroup Inc. acquired a new position in Prelude Therapeutics during the fourth quarter worth about $124,000. Finally, Royal Bank of Canada raised its stake in Prelude Therapeutics by 21.8% during the first quarter. Royal Bank of Canada now owns 3,449 shares of the company’s stock worth $150,000 after acquiring an additional 618 shares in the last quarter. 91.62% of the stock is owned by institutional investors and hedge funds.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas.

See Also: How is net asset value different from market price?

Get a free copy of the Zacks research report on Prelude Therapeutics (PRLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.